NCT02575807 - Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 8, 2016

Primary Completion Date

April 26, 2018

Study Completion Date

May 8, 2018

Conditions

Platinum-resistant Ovarian CancerPlatinum-resistant Fallopian CancerPlatinum-resistant Peritoneal Cancer

Interventions

BIOLOGICAL

CRS-207

via IV infusion

DRUG

Epacadostat

PO BID

BIOLOGICAL

Pembrolizumab

via IV infusion

Trial Locations (12)

University of Pennsylvania Health System, Philadelphia

Fox Chase Cancer Center, Philadelphia

Johns Hopkins University, Baltimore

University of Virginia Health System, Charlottesville

University of Florida, Gainesville

Northwestern University, Chicago

Scottsdale Healthcare Hospitals DBA HonorHealth, Scottsdale

Stanford Cancer Center, Stanford

Oregon Health and Science University, Portland

Virginia Mason Medical Center, Seattle

Princess Margaret Cancer Centre, Toronto

CHUM - Centre Hospitalier de l'Université de Montréal, Montreal